On November 20, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, reported its collaboration with Idaho Urologic Institute, PA (IUI) in the Cchek early cancer detection study (Press release, Anixa Biosciences, NOV 20, 2019, View Source [SID1234551536]). IUI will provide patient samples for Anixa’s ongoing prostate cancer study, including support of clinical validation of Anixa’s Cchek Prostate Cancer Confirmation test.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IUI is one of several sites across the U.S. participating in this study. Dr. Lisa Parillo will serve as the Principal Investigator for the study at IUI.

Dr. Amit Kumar, Chief Executive Officer of Anixa, stated, "We are pleased to have IUI join our expanding group of Cchek collaboration partners. Our large and growing team of influential collaborators has been key to the development of our artificial intelligence driven liquid biopsy for early cancer detection. We look forward to IUI’s participation as we continue the clinical validation phase of the Cchek Prostate Cancer Confirmation test, in preparation for commercial launch later this year."

About Cchek
Cchek is an early cancer detection technology, which measures a patient’s immunological response to a malignancy by analyzing immune system cells in peripheral blood. The goal is to utilize the technology to determine a patient’s cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure. Further, conventional methods using current cancer screening tests often lack accuracy and reliability. Anixa’s orthogonal approach using flow cytometry coupled with artificial intelligence provides an alternative method with greater affordability, efficacy and efficiency. To date, Anixa has successfully used Cchek to detect the presence of 20 different cancers including lung, colon, breast and prostate. The robust cancer detection performance of Cchek makes it a platform from which multiple cancer diagnostic tests may be developed. The first such test, a prostate cancer confirmation test, is slated for commercial launch by the end of 2019.